Articles related to COMBINATION THERAPY

The FDA’s recent approval of Pombiliti + Opfolda just expanded treatment options for the rare inherited lysosomal disorder.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.

Discover how the FLAURA2 trial’s findings on combination therapy could revolutionize initial treatment plans for NSCLC patients with EGFR mutations. Learn more about the significant extension in progression-free survival and its potential clinical implications.

The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.

Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.

Discover how Roswell Park’s phase 2 clinical trials are exploring the potential of propranolol to enhance the efficacy of immunotherapies in treating esophageal cancer. This could represent a significant shift in treatment protocols.